02.26.2019 Issue 440

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

ICER: Spinraza, Zolgensma Offer
'Substantial Health Benefits'

Friday, February 22

Biogen’s Spinraza and Novartis and AveXis’ Zolgensma provide “substantial health benefits” in the treatment of spinal muscular atrophy, according to a new assessment by ICER.

Opinion: Abandon QALY Metric in Cost-Effectiveness Reviews

Unsealed Testimony Reveals Details About Amazon, Berkshire and J.P. Morgan Health Venture

Column: Tap Pharmacists to Help Wrangle Drug Prices

STAT Offering Webinar on Congress, Drug Prices

The 7 Pharma Execs Set to Testify Before Congress

Government: Drug Spending to Accelerate, Hit 6.1% Per Year By 2020

Drug’s $375K Price Tag Leads to Rationing, Criticism


Senior Principal, Pricing Market Access

Senior Systematic Reviewer

Sr Principal/Principal Health Economics

Cardiovascular Medical Content Writer with AMCP Dossier and HEOR Knowledge

Industry Spotlight


Conferences Webinars
Hub and SPP Model Optimization
    February 26-27, Philadelphia, Pennsylvania

12th Annual Medicaid Managed Care Summit
    February 26-27, Washington, D.C.

Patient Assistance and Access Programs 2019
    March 4-6, Baltimore, Maryland

9th Orphan Drugs and Rare Diseases Global Congress 2019 Europe
    March 4-6, London, U.K.

Clinical Statistics for Non-Statisticians
    February 27

Is the New Congress Ready to Lower Drug Costs?
    February 27

Patient-Reported Outcomes in Clinical Drug Development
    February 27

Amplifying the Patient Voice: Policy Solutions for Improving Patient-Reported Measures in Oncology Value-Based Payment Programs
    February 28


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
                   Truven         
              Evidera    HealthCore    University of FL
      Xcenda    OM1    Parexel    Jefferson    Dymaxium    
      Precision Xtract    Pharmerit    eMax Health    Sciformix
       Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn